TOKYO, May 11 (Pulse News Wire) – Teijin Limited (3401.T) reported lower operating profit for fiscal year 2025 due to impairment losses in its aramid and healthcare segments. Revenue declined by -¥132.3 billion compared to the previous year, while operating profit decreased by -¥1.800 billion.
Despite these challenges, the company expects improved performance in 2026, projecting a rise in operating profit to ¥4.200 billion. In 2025, the healthcare division saw increased sales of medical devices but faced significant impairment charges related to diabetes treatment agents. Meanwhile, the materials segment experienced reduced profitability due to large maintenance shutdowns and unfavorable sales mix.
However, Teijin anticipates growth in 2026 driven by operational improvements and cost reductions across various product lines. For the upcoming fiscal year, Teijin plans to maintain a stable dividend policy, forecasting a per-share payout of ¥50, split evenly between interim and final payments. The company remains committed to balancing shareholder returns with strategic investments aimed at long-term growth and sustainability.
🟡 Confidence: Standard AI-translated content.